Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab in children with steroid- and calcineurin-inhibitor-resistant nephrotic syndrome
2015-000569-30Phase 2Completed
- Sponsor
- Istituto Giannina Gaslini
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ofatumumab in nephrosis (2 arms), sponsored by Istituto Giannina Gaslini. Primary endpoint: Complete or partial disease remission at 6 months from randomization. Started Nov 2020; status: completed.
02
Drugs
ofatumumab
03
Conditions
nephrosis
Beyond the preview
Go deeper on 2015-000569-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000569-30.